The takeaway
Syndax Pharmaceuticals Inc shows a pronounced seasonal pattern over 10 years of data — strongest in January (+3.4%) and softest in October (−8.6%).
Right now
In July, the stock has risen 60% of years, averaging +2.0% — essentially in line with the S&P 500.
The full picture
Syndax Pharmaceuticals Inc's most dependable month has been January, higher in 6 of 9 years; October has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in August (+10.2 pts); it has trailed the market most in October (−9.7 pts).
“vs S&P” is Syndax Pharmaceuticals Inc’s average for a month minus the S&P 500’s average for that same month — isolating Syndax Pharmaceuticals Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, January has closed higher 40% of the time versus 67% across the last 10 years — the pattern is weakening.
Figures are the typical (median) January return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
No single month dominates — the stock carries a broad upward tilt, with 6 months rising more often than they fall and January (6 of 9 Januaries) nominally in front.
Its average (+3.4%) and median (+3.8%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even January ranges by 15.6% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: January has cleared the S&P 500 by +3.6 points above the index. That consistency sets it apart from the field, where the average stock manages January only about 53% of the time.
The strength clusters rather than stands alone — November–January forms a firm stretch that carries much of the year. The weaker half of the year is plainer: October has been the soft spot — the weakest of 4 months that average a loss (−8.6%), and the edge isn't year-round — the stock has trailed the S&P 500 in October, May, and September. Its roughest month on record was a −42.9% October in 2018 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, January's last five years slipping below its longer-run record.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (January), its worst (October), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (January, +3.4%) has run well ahead of its worst (October, −8.6%) — the heatmap above shows how steady that gap has been year to year.
January has been the strongest, averaging +3.4% and closing higher in 6 of 9 years since 2016.
It's the weakest, averaging −8.6% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade